赵毅教授：Efficacy and safety of brivanib as frist-line or second-line therapy in Asian and non-Asian patients with advanced hepatocellular carcinoma(HCC)：Outcomes from a phase 2 study and a retrospective analysis using modified RECIST criteria for HCC

转载请注明来自丁香园
发布日期：2010-09-18 13:43 文章来源：丁香园
分享到：收藏夹新浪微博腾讯微博开心网豆瓣社区人人网
点击次数：

Efficacy and safety of brivanib as frist-line or second-line therapy in Asian and non-Asian patients with advanced hepatocellular carcinoma(HCC)：Outcomes from a phase 2 study and a retrospective analysis using modified RECIST criteria for HCC

赵毅教授台北荣民医院

赵毅教授主题讲座

<< < 1 2 3 > >>

编辑: yishuitan

丁香园——医学、药学、生命科学专业论坛

历届专题更多 >>

友情链接

热门点评更多 >>

赵毅教授：Efficacy and safety of brivanib as frist-line or second-line therapy in Asian and non-Asian patients with advanced hepatocellular carcinoma(HCC)：Outcomes from a phase 2 study and a retrospective analysis using modified RECIST criteria for HCC

以下网友留言只代表网友个人观点，不代表网站观点

丁香园——医学、药学、生命科学专业论坛

历届专题 更多 >>

友情链接

热门点评 更多 >>

赵毅教授：Efficacy and safety of brivanib as frist-line or second-line therapy in Asian and non-Asian patients with advanced hepatocellular carcinoma(HCC)：Outcomes from a phase 2 study and a retrospective analysis using modified RECIST criteria for HCC

以下网友留言只代表网友个人观点，不代表网站观点

历届专题更多 >>

热门点评更多 >>